• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清肺癌标志物 6 水平可预测间质性肺疾病的疾病进展。

Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.

机构信息

Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.

出版信息

PLoS One. 2020 Dec 17;15(12):e0244114. doi: 10.1371/journal.pone.0244114. eCollection 2020.

DOI:10.1371/journal.pone.0244114
PMID:33332430
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7746162/
Abstract

Disease progression (DP) in interstitial lung disease (ILD) is variable and difficult to predict. In previous reports, serum Krebs von den Lungen-6 (KL-6) was suggested to be useful in diagnosing and predicting survival in ILD. The aim of our study was to investigate the usefulness of serum KL-6 as a predictor of DP in ILD. Clinical data of 199 patients with ILD (idiopathic pulmonary fibrosis: 22.8%) were prospectively collected and serum KL-6 levels were measured. DP was defined as a relative decline in forced vital capacity (FVC) ≥ 10%, acute exacerbation, or death during follow-up. The median follow-up period was 11.1 months. The mean age of the subjects was 62.2 years, and 59.8% were male. DP occurred in 21.6% of patients. The progressed group showed lower FVC, lower diffusing capacity for carbon monoxide, lower the minimum oxygen saturation during the 6-minute walk test, higher fibrosis scores on high-resolution computed tomography, and higher KL-6 levels (826.3 vs. 629.0 U/mL; p < 0.001) than those of the non-progressed group. In receiver operating characteristic curve analysis, serum KL-6 levels were a significant predictor of DP in ILD (area under the curve = 0.629, p = 0.009, and the optimal cut-off level was 811 U/mL). In multivariable Cox analysis, high serum KL-6 levels (≥ 800 U/mL) were only independently associated with DP in ILD (HR 2.689, 95% CI 1.445-5.004, P = 0.002). Serum KL-6 levels might be useful to predict DP in patients with ILD.

摘要

肺纤维化(IPF)是特发性间质性肺炎(IIP)的一种组织学类型,其疾病进展(DP)是可变的,难以预测。在以前的报告中,血清 Krebs von den Lungen-6(KL-6)被认为对诊断和预测 IIP 患者的生存率有用。本研究旨在探讨血清 KL-6 作为 IIP 患者 DP 预测因子的作用。前瞻性收集了 199 例 IIP 患者(特发性肺纤维化:22.8%)的临床数据,并检测了血清 KL-6 水平。DP 定义为随访期间用力肺活量(FVC)相对下降≥10%、急性加重或死亡。中位随访时间为 11.1 个月。受试者的平均年龄为 62.2 岁,59.8%为男性。21.6%的患者发生 DP。进展组的 FVC、一氧化碳弥散量、6 分钟步行试验时的最低氧饱和度、高分辨率计算机断层扫描的纤维化评分和 KL-6 水平(826.3 vs. 629.0 U/mL;p < 0.001)均低于未进展组。在受试者工作特征曲线分析中,血清 KL-6 水平是 IIP 患者 DP 的显著预测因子(曲线下面积=0.629,p=0.009,最佳截断值为 811 U/mL)。在多变量 Cox 分析中,高血清 KL-6 水平(≥800 U/mL)是 IIP 患者 DP 的唯一独立预测因子(HR 2.689,95%CI 1.445-5.004,P=0.002)。血清 KL-6 水平可能有助于预测 IIP 患者的 DP。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35cc/7746162/0b0bf79ee493/pone.0244114.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35cc/7746162/7964bbe3fc10/pone.0244114.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35cc/7746162/6971acb1e38f/pone.0244114.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35cc/7746162/b2db066ef05e/pone.0244114.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35cc/7746162/0b0bf79ee493/pone.0244114.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35cc/7746162/7964bbe3fc10/pone.0244114.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35cc/7746162/6971acb1e38f/pone.0244114.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35cc/7746162/b2db066ef05e/pone.0244114.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35cc/7746162/0b0bf79ee493/pone.0244114.g004.jpg

相似文献

1
Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.血清肺癌标志物 6 水平可预测间质性肺疾病的疾病进展。
PLoS One. 2020 Dec 17;15(12):e0244114. doi: 10.1371/journal.pone.0244114. eCollection 2020.
2
Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.血清 Krebs von den Lungen-6 水平升高与系统性硬化症:肺纤维化和疾病严重程度的标志物。
Rheumatol Int. 2018 May;38(5):813-819. doi: 10.1007/s00296-018-3987-3. Epub 2018 Feb 17.
3
Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.疾病早期血清克雷伯斯-冯-登-伦根-6升高可预测系统性硬化症和间质性肺病患者随后的肺功能恶化。
J Rheumatol. 2016 Oct;43(10):1825-1831. doi: 10.3899/jrheum.160339. Epub 2016 Aug 1.
4
Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.候选血清生物标志物在系统性硬化症相关间质性肺病中的表现。
Arthritis Rheumatol. 2019 Jun;71(6):972-982. doi: 10.1002/art.40815. Epub 2019 Apr 26.
5
Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.血清 KL-6 水平反映了与结缔组织病相关的间质性肺病的严重程度。
Arthritis Res Ther. 2019 Feb 14;21(1):58. doi: 10.1186/s13075-019-1835-9.
6
Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort.Krebs von den Lungen (KL-6) 对间质性肺病的诊断价值:一项欧洲前瞻性队列研究。
Arch Bronconeumol. 2024 Jun;60(6):350-355. doi: 10.1016/j.arbres.2024.03.028. Epub 2024 Apr 6.
7
Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease.KL-6 在类风湿关节炎相关间质性肺病中的预后作用。
PLoS One. 2020 Mar 12;15(3):e0229997. doi: 10.1371/journal.pone.0229997. eCollection 2020.
8
Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis.血液 Krebs von den Lungen-6 水平可预测特发性肺纤维化患者抗纤维化治疗的反应。
Respir Res. 2022 Dec 9;23(1):334. doi: 10.1186/s12931-022-02273-6.
9
The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.血清 Krebs von den lungen-6 在结缔组织病相关间质性肺疾病中的诊断标志物价值。
BMC Pulm Med. 2020 Jan 8;20(1):6. doi: 10.1186/s12890-019-1043-z.
10
[Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].[抗合成酶综合征相关间质性肺病和特发性肺纤维化中肺功能检查及KL-6的特征与临床意义]
Zhonghua Yi Xue Za Zhi. 2020 Mar 17;100(10):748-752. doi: 10.3760/cma.j.cn112137-20191008-02166.

引用本文的文献

1
Correlation between CT-based phenotypes and serum biomarker in interstitial lung diseases.基于 CT 的表型与间质性肺疾病血清生物标志物的相关性。
BMC Pulm Med. 2024 Oct 19;24(1):523. doi: 10.1186/s12890-024-03344-8.
2
Clinical Utility of Bronchoalveolar Lavage Neutrophilia and Biomarkers for Evaluating Severity of Chronic Fibrosing Interstitial Lung Diseases.支气管肺泡灌洗中性粒细胞增多及生物标志物在评估慢性纤维化间质性肺疾病严重程度中的临床应用
Cureus. 2023 Jul 19;15(7):e42162. doi: 10.7759/cureus.42162. eCollection 2023 Jul.
3
[Interstitial Lung Disease].

本文引用的文献

1
Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases.韩国间质性肺疾病患者中 Nanopia Krebs von den Lungen 6 检测的分析和临床性能。
Ann Lab Med. 2019 May;39(3):245-251. doi: 10.3343/alm.2019.39.3.245.
2
Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.肺腺癌 6 与胸部高分辨率 CT 评分在评估间质性肺疾病患者严重程度中的相关性。
Pulmonology. 2019 May-Jun;25(3):143-148. doi: 10.1016/j.pulmoe.2018.05.008. Epub 2018 Jul 11.
3
Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.
[间质性肺疾病]
Open Respir Arch. 2023 May 8;5(2):100248. doi: 10.1016/j.opresp.2023.100248. eCollection 2023 Apr-Jun.
4
Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review.新冠后肺纤维化:事实、挑战与未来:一篇叙述性综述
Pulm Ther. 2023 Sep;9(3):295-307. doi: 10.1007/s41030-023-00226-y. Epub 2023 May 20.
5
Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease.抗合成酶综合征相关间质性肺病患者进行性肺纤维化的预测。
Clin Rheumatol. 2023 Jul;42(7):1917-1929. doi: 10.1007/s10067-023-06570-3. Epub 2023 Mar 17.
6
Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease.血清KL-6作为纤维化间质性肺疾病任何阶段病情进展的生物标志物。
J Clin Med. 2023 Feb 1;12(3):1173. doi: 10.3390/jcm12031173.
7
Diagnosing lung involvement in inflammatory rheumatic diseases-Where do we currently stand?诊断炎症性风湿性疾病中的肺部受累——我们目前的进展如何?
Front Med (Lausanne). 2023 Jan 11;9:1101448. doi: 10.3389/fmed.2022.1101448. eCollection 2022.
8
Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis.血液 Krebs von den Lungen-6 水平可预测特发性肺纤维化患者抗纤维化治疗的反应。
Respir Res. 2022 Dec 9;23(1):334. doi: 10.1186/s12931-022-02273-6.
9
Clinical Utility of Circulating Pneumoproteins as Diagnostic and Prognostic Biomarkers in COVID-19: A Systematic Review and Meta-analysis.循环肺炎蛋白作为COVID-19诊断和预后生物标志物的临床应用:系统评价和荟萃分析
Infect Dis Ther. 2022 Oct;11(5):1981-1998. doi: 10.1007/s40121-022-00686-w. Epub 2022 Aug 25.
10
Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review.类风湿关节炎间质性肺疾病的新型生物标志物、诊断与治疗方法——一项叙述性综述
Biomedicines. 2022 Jun 9;10(6):1367. doi: 10.3390/biomedicines10061367.
大巴黎地区一个多民族县的间质性肺疾病的患病率和发病率。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.02419-2016. Print 2017 Aug.
4
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.特发性肺纤维化急性加重:国际工作组报告。
Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75. doi: 10.1164/rccm.201604-0801CI.
5
Idiopathic interstitial pneumonias: do HRCT criteria established by ATS/ERS/JRS/ALAT in 2011 predict disease progression and prognosis?特发性间质性肺炎:2011年美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科协会制定的高分辨率计算机断层扫描标准能否预测疾病进展和预后?
Radiol Med. 2015 Oct;120(10):930-40. doi: 10.1007/s11547-015-0526-0. Epub 2015 Mar 6.
6
Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis.基线KL-6可预测特发性肺纤维化急性加重风险增加。
Respir Med. 2014 Jul;108(7):1031-9. doi: 10.1016/j.rmed.2014.04.009. Epub 2014 Apr 26.
7
Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan.日本特发性肺纤维化生物标志物研究进展。
Biosci Trends. 2013 Aug;7(4):172-7.
8
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.美国胸科学会/欧洲呼吸学会官方声明:特发性间质性肺炎的国际多学科分类的更新。
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48. doi: 10.1164/rccm.201308-1483ST.
9
Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.过敏性肺炎:诊断与病理生物学的新认识。
Am J Respir Crit Care Med. 2012 Aug 15;186(4):314-24. doi: 10.1164/rccm.201203-0513CI. Epub 2012 Jun 7.
10
Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.KL-6/MUC1在间质性肺疾病临床管理中的应用
Respir Investig. 2012 Mar;50(1):3-13. doi: 10.1016/j.resinv.2012.02.001. Epub 2012 Mar 8.